#### Developmental trajectories in infants and pre-school children with Neurofibromatosis 1

Hannah Slevin<sup>1\*</sup>, MRCPsych, Fiona Kehinde<sup>1\*</sup>, MB BChir MA (Cantab), Jannath Begum-Ali<sup>2</sup>, PhD, Ceri Ellis<sup>1</sup>, PhD, Emma Burkitt-Wright<sup>3,4</sup>, MbChB, PhD, Jonathan Green<sup>1,5</sup>, FRCPsych, Mark H. Johnson<sup>2,6</sup>, PhD, Greg Pasco<sup>7</sup>, PhD, Tony Charman<sup>7</sup>, PhD, Emily J.H Jones<sup>2</sup>, PhD, and Shruti Garg<sup>1,5</sup>, PhD on behalf of the EDEN-STAARS team\*\*.

\*Contributed equally as first authors

\*\* A complete list of study group members appears in the Acknowledgments

Affiliations <sup>1</sup>Division of Psychology, Communication and Human Neuroscience, School of Health Sciences, University of Manchester, Manchester, United Kingdom,

<sup>2</sup>Centre for Brain and Cognitive Development and Department of Psychological Sciences, Birkbeck, University of London, London, United Kingdom,

<sup>3</sup>Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom,

<sup>4</sup>Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom,

<sup>5</sup>Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom,

<sup>6</sup>Department of Psychology, University of Cambridge, Cambridge, United Kingdom, <sup>7</sup>Psychology Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

Address correspondence to: Dr Shruti Garg shruti.garg@manchester.ac.uk

Short title: Developmental trajectories in NF1 infants and children

Conflict of Interest Disclosures (includes financial disclosures): TC has served as a paid consultant to F. Hoffmann-La Roche Ltd. and Servier; and has received royalties from Sage Publications and Guilford Publications. The other authors have no conflicts of interest to disclose.

Funding/Support: This study was supported by Action for Medical Research (GN2385), Rosetrees Trust (A2213), Medical Research Council (MR/K021389/1; MR/T003057/1) and MO (MO14PP 83). This study was also supported by the EU-AIMS and AIMS-2-TRIALS programmes funded by the Innovative Medicines Initiative Joint Undertaking Grant No.115300 and No. 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme, with contributions from the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and funding from Autism Speaks, Autistica and SFARI. This work was also supported by Action for Medical Research, Great Ormond Street Hospital Children's Charity and the Bailey Thomas Charitable Fund (GN2385), Rosetrees Trust (A2213). Shruti Garg is a Francis Collins Scholar supported by Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the John Hopkins University. Jonathan Green is supported by NIHR Senior Investigator Award. Hannah Slevin is an NIHR Academic Clinical Fellow and Fiona Kehinde is a Houghton-Dunn research associate.

WHE of the funder of the second s

medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299174; this version posted December 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders.

Clinical Trial Registration (if any): The studies involving human participants were approved by Greater Manchester Central Research Ethics committee (16/NW/0324) and National Research Ethics Service London Central Ethical Committee (16/EE/0167 and 06/MRE02/73). Written informed consent for study participation was obtained from the participant's legal guardian/next of kin.

Data sharing statement: Deidentified participant data is available through the STAARS network via data sharing procedures that comply with ethical requirements, due to the sensitive nature of the data collected. Available at: https://www.basisnetwork.org/. There is no known end date of data availability.

Abbreviations: NF1: neurofibromatosis type 1; ADHD: attention deficit hyperactivity disorder; MSEL: Mullen Scales of Early Learning; VABS: Vineland Adaptive Behavior Scales; ADOS-2: Autism Diagnostic Observation Schedule; BOSA-MV: Brief Observation of Symptoms of Autism for Minimally Verbal children; ADI-R: Autism Diagnostic Interview-Revised; CBCL: Child Behavior Checklist.

#### **Article Summary**

This prospective study examines cognitive and adaptive functioning, ADHD and autism traits in children with Neurofibromatosis 1 aged 5-36 months versus typically developing children.

#### What's Known on This Subject

Pre-school children with NF1 demonstrate cognitive, behavioural and social differences compared to peers. Evidence suggests that children with NF1 have higher rates of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder. However, the age at which differences emerge remains unclear.

#### What This Study Adds

This study examined trajectories from infancy of children with NF1 to detect the earliest age of onset of cognitive and behavioural differences. Differences between NF1 and TD infants emerged from 24 months of age.

#### **Contributors Statement Page**

Dr Hannah Slevin and Dr Fiona Kehinde led the analysis, interpreted the results, drafted the manuscript and commented on the revisions.

Dr Jannath Begum-Ali led the fieldwork assessments, led data entry and initial analysis, led the quality control of phenotypic data and contributed to the critical review of the manuscript.

Dr Ceri Ellis contributed to the fieldwork assessments, led data entry, led the quality control of phenotypic data and contributed to the critical review of the manuscript.

Dr Emma Burkitt-Wright identified and recruited participants and contributed to the critical review of the manuscript.

Professor Jonathan Green conceptualised the study and design, gained funding, critically reviewed and revised the manuscript.

Professor Mark H. Johnson conceptualised and designed the study, gained funding and critically reviewed and revised the manuscript.

Dr Greg Pasco contributed to data collection and critically reviewed the manuscript.

Professor Tony Charman conceptualised and designed the study, supervised the field-work and critically reviewed the manuscript.

Professor Emily Jones conceptualised the study design, gained funding, , supervised the field-work and critically reviewed and revised the manuscript.

Dr Shruti Garg conceptualised the study design, gained funding, led the recruitment, supervised the fieldwork and analyses, contributed to interpretation of findings and critically reviewed and revised the manuscript.

The EDEN-STAARS team recruited participants and conducted all fieldwork assessments.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

## Abstract

**Objective:** This prospective cohort study examines the cognitive, behavioural, ADHD trait and autism symptom development in infant and pre-school children with Neurofibromatosis 1 (NF1) compared with typically developing (TD) children without a family history of neurodevelopmental conditions.

**Methods:** Data from standardised tests was gathered at 5, 10, 14, 24 and 36 months of age (NF1 n=35, TD n=29). Developmental trajectories of cognitive and adaptive behavioural development from 5 to 36 months were analysed using linear mixed modelling. Measures of ADHD and autism traits were assessed at 24 and 36 months.

**Results:** The developmental trajectory of cognitive skills (all domains of the Mullen Scales of Early Learning -MSEL) and behavioural skills (four domains of the Vineland Adaptive Behaviour Scale -VABS) differed significantly between NF1 and TD groups. Post-hoc tests demonstrated that the NF1 participants scored significantly lower than TD participants at 24 months on all MSEL and VABS domains. The NF1 cohort demonstrated higher mean autism and ADHD traits at 24 months and 14% of the NF1 cohort met a research diagnostic classification for autism at 36 months.

**Conclusion**: By 24 months of age, the NF1 cohort show lower cognitive skills and adaptive behaviour and higher levels of autism and ADHD traits as compared to TD children.

### 1 INTRODUCTION

2	Neurofibromatosis 1 (NF1) is a single gene neurocutaneous condition, with a birth incidence
3	of 1 in 2700.1 50% of cases arise through autosomal dominant inheritance from a parent, and
4	50% via a sporadic pathogenic variant of the tumour-suppressor NF1 gene on chromosome
5	17q11.2. This gene codes for the protein neurofibromin, which plays a role in regulating
6	neuronal cell development. <sup>2</sup> NF1 is characterised by phenotypic variability, and clinical
7	diagnosis is based on the revised National Institute of Health (NIH) criteria. <sup>3</sup>
8	Many children with NF1 experience cognitive and behavioural difficulties which impact their
9	quality of life. Overall intellectual ability is only slightly lower than children who do not have
10	NF1, however specific cognitive deficits impact perceptual (particularly visuospatial) skills,
11	executive functioning, adaptive behaviour, attention and motor skills. <sup>4,5</sup> Research also
12	indicates high rates of co-occurring conditions such as Autism Spectrum Disorder
13	(henceforth referred to as autism) (29%) and Attention Deficit Hyperactivity Disorder
14	(ADHD) (50%). <sup>6,7</sup>
15	The majority of studies analysing the cognitive, social and behavioural phenotype in NF1
16	have concentrated on school-aged children. Several cross-sectional studies have focused on
17	the pre-school period, which consistently demonstrate that young children with NF1 show
18	cognitive, behavioural and social differences compared to age-matched controls. <sup>2,4,8-12</sup>
19	However, the age and sequence at which these differences begin to emerge is not fully
20	understood. Understanding this is crucial for identifying early markers of later
21	neurodevelopmental outcomes, and has clinical implications for screening and intervention,
22	particularly educational planning. <sup>13</sup>
23	Two previous studies have analysed trajectories of cognitive development in toddlers. <sup>14,15</sup>

Lorenzo et al (2015) assessed the early development of 39 children with NF1 aged 21, 30 and

40 months compared with matched controls; the NF1 cohort demonstrated lower cognitive
functioning than controls.<sup>14</sup> Wessel et al (2013) assessed 124 infants with NF1 at a range of
ages (0-8) using parental report measures. Gross and fine motor delays were found to emerge
aged 3-5, whereas academic delays tended to present at a later age.<sup>15</sup> However, the majority
of the cohort had just one assessment.

Previous papers from our group examined trajectories of cognitive and adaptive behavioural development in infants with NF1 aged 5 to 14 months compared with typically developing (TD) children.<sup>13</sup> At this early stage in development, no group differences were observed in trajectories of cognitive and adaptive functioning, nor differences on social communication measures. However, early differences in neural processing including auditory processing and excitation/inhibition balance were observed, both of which were related to later autistic traits.<sup>16,17</sup>

Our study aim is to examine the early cognitive, behavioural, autism and ADHD trait development of infants and pre-school aged children with NF1, compared with a cohort of TD children. Our objectives were to build on the earlier work of our team<sup>13</sup> by examining longitudinal trajectories of cognitive and behavioural development from 5-36 months, and ADHD trait development at 24 and 36 months. We also aimed to examine emergence of autism traits at 24 and 36 months.

We hypothesised that children with NF1 would have lower cognitive and adaptive
functioning over time, and higher levels of ADHD and autism traits compared with TD
children. Based on our previous work, we interrogate whether differences begin to emerge at
age 24 or 36 months. To our knowledge, this is the first study to examine cognitive and
behavioural development from infancy in children with NF1 using both parental report and
objective assessment measures. This prospective approach is critical in avoiding

6

ascertainment bias seen with older children, where participants may be more likely toparticipate if they are experiencing developmental delays.

#### 51 METHODS

52 The Early Development in NF1 (EDEN) study is a UK-based prospective longitudinal cohort study investigating early development in infants and children with NF1. Participants were 53 enrolled through regional genetic centres and NF1 charities. Participants in the TD group 54 were recruited from the Studying Autism and ADHD in at Risk Siblings (STAARS) study at 55 the Centre for Brain and Cognitive Development, Birkbeck, University of London. 56 57 Participants were assessed at 5, 10, 14, 24 and 36 months of age. Rolling recruitment was conducted between 2016-2019. 58 Inclusion criteria for the NF1 cohort included a) infants up to 16 months of age at the time of 59 recruitment b) NF1 diagnosed via testing of cord blood samples or clinical diagnosis. 60 61 Inclusion criteria for the TD group included a) infants up to 16 months of age at the time of recruitment b) no first-degree relatives with known genetic conditions, autism or Attention 62 Deficit Hyperactivity Disorder (ADHD) c) no parent-reported developmental issues d) full-63 64 term birth (gestational age at least 36 weeks). Exclusion criteria for both groups included a) conditions which might make it difficult for the 65 infant to participate, including serious physical complications of NF1 b) significant hearing 66 or visual impairments c) significant prematurity d) parents with significant learning 67

68 difficulties or who were unable to give informed consent.

69 Procedural details are included in Supplementary materials.

#### 70 Measures

#### 71 Maternal education

- 72 Maternal education was classified as either primary, secondary, undergraduate or
- 73 postgraduate (1,2,3 or 4) (**Table 1**). This has been shown to be significantly associated with
- trajectories of cognitive and adaptive functioning at 5, 10 and 14 months in this population.<sup>15</sup>

#### 75 Cognitive and adaptive behavioural skills

76 The Mullen Scales of Early Learning (MSEL),<sup>18</sup> a standardised assessment for children aged

up to 68 months, was used to assess cognitive functioning at all five time points. Five

domains were assessed, including Visual Reception, Fine Motor, Receptive Language,

- 79 Expressive Language skills (all measured as T-scores) and an Early Learning Composite
- 80 (ELC) (Standard Score).
- 81 The Vineland Adaptive Behavior Scale (VABS),<sup>19</sup> a parent-report questionnaire, was used to

82 assess adaptive behavioural skills at all five time points. Five domains were assessed,

- 83 including Communication, Daily Living Skills, Socialisation, Motor skills and an Adaptive
- 84 Behaviour Composite score. Analyses used Standard Scores.

#### 85 ADHD traits

- 86 The Child Behaviour Checklist (CBCL) for ages 1.5-5,<sup>20</sup> a parent-report questionnaire, was
- 87 used to assess ADHD traits (inattention/hyperactivity) at 24 and 36 month time points. T-
- 88 scores were used for the DSM-orientated Attention Deficit Hyperactivity problems scale. T-
- scores of 70 are in the clinically significant range, and 65-69 considered borderline.

#### 90 *Autism traits*

91 The Autism Diagnostic Observation Schedule (ADOS-2), a semi-structured assessment of
92 social communication, social interaction and imaginative play for individuals suspected to

93	have autism, <sup>21,22</sup> was utilised at 24 and 36 months. Due to social distancing constraints
94	necessitated by the Covid-19 pandemic, some assessments instead utilised the Brief
95	Observation of Symptoms of Autism for Minimally Verbal children (BOSA-MV), an
96	observational measure designed to be administered remotely. <sup>23</sup> Table 3 outlines the
97	participant numbers at each timepoint who were administered ADOS-2 versus BOSA.
98	The Autism Diagnostic Interview-Revised (ADI-R), an investigator-based semi-structured
99	interview for parents, <sup>24</sup> was carried out at 36 months.
100	The Supplementary Materials outline diagnostic thresholds on the ADOS-2, BOSA and
101	ADI-R, and detail how a research classification of autism was determined at 36 months.
102	Statistical analyses
103	Statistical analyses were performed using IBM SPSS Statistics 28.0.0.0. Linear mixed
104	modelling was used to analyse the change in cognition (MSEL), adaptive behaviour (VABS)
105	and ADHD traits (CBCL DSM-ADHD subscale) over time. For each subscale, overall group
106	differences were modelled using fixed effects (group, timepoint and sex) and random effects
107	(ID - individual variation). Maternal education was included as a co-variate within the
108	model. <sup>15</sup> Maternal education significantly differed between groups, with mothers of TD
109	children more likely to have a post-graduate education (Median NF1: 2, TD: 4 $X^2(2) = 19.79$ ,
110	p<0.001).
111	In all models, sex was non-significant (Table 2). The NF1 group was significantly older than
112	the TD group at 5 months (t = $3.09$ , $95\%$ CI $5.36$ to $25.72$ days, p = $0.004$ , d $1.00$ ) and at $36$
113	months (t = 3.70, 95% CI 54.60 to 186.36 days, p = <0.001, d 0.91). Age in days was not
114	included in the model as a fixed effect, as this had already been corrected for by using age-
115	corrected T scores (MSEL and CBCL) and age-corrected standard scores (VABS). Post hoc

T-tests were carried out to further explore group differences on the MSEL and VABS at eachtimepoint.

- 118 Missing data were imputed using the maximum likelihood option. A p value of <0.05 was
- 119 considered as significant. For post-hoc tests, a corrected p value of <0.01 was considered
- significant. Pearson Chi-squared tests were carried out for proportion of participants meeting
- autism threshold on the ADOS-2/BOSA/ADI-R (as outlined in the Supplementary
- 122 materials). Mann-Whitney non-parametric analyses were used to compare ADI-R subscale
- 123 means due to non-normality.

#### 124 **RESULTS**

125 35 children with NF1 and 29 TD participants were recruited. Table 1 provides further details

126 of the demographic characteristics and number of participants per measure. 32 of the

127 participants with NF1 had an inherited pathogenic variant, 2 arose de novo and 1 had an

128 unknown mechanism of inheritance.

### 129 Trajectories of cognitive and adaptive behavioural development

Table 2 summarises the results of the linear mixed models for each of the measures described
below and post-hoc statistics are presented in Supplementary Materials.

132 On the MSEL, the developmental trajectory of children with NF1 differed significantly

133 compared to the trajectory of TD children across all subscales (Visual Reception, Fine Motor,

134 Receptive Language, Expressive Language, Early Learning Composite), with slower progress

- in the NF1 group. There was also a significant effect of Timepoint within the model;
- 136 cognitive skills increased for all children as they aged, irrespective of group membership. The
- 137 interaction between Group and Timepoint also reached statistical significance for all MSEL
- 138 subscales (Figure 1). Pairwise comparisons showed significant differences between the NF

and TD groups on all MSEL domains at 5, 24 and 36 months. Only lower Fine Motor skills
were observed at 10 months in the NF1 group, with no differences between the groups at 14
months.

The trajectories of adaptive behavioural skills development were significantly different in 142 NF1 when compared with TD children on four subscales of the VABS; Communication 143 abilities, Daily living skills, Motor Skills and the Adaptive behaviour Composite domain, 144 with slower progress in the NF1 group. However, there was no significant difference between 145 children with NF1 and TD children on the Socialization domain. Adaptive behavioural skills 146 increased significantly for all children over time irrespective of group membership. The 147 interaction between Group and Timepoint also reached statistical significance for all VABS 148 149 subscales (Figure 2). Pairwise comparisons showed that the NF1 participants scored 150 significantly lower than TD participants in Daily living skills, Motor skills and the Adaptive Behavior Composite at 10 months, on all VABS domains at 24 months, but only on 151

152 communication at 36 months.

#### 153 ADHD trait development

Children with NF1 showed higher mean levels of ADHD traits on the CBCL DSM-ADHD
subscale than TD children (Figure 3 and Table 2). 10.5% of NF1 participants at 36 months
had a T-score over 65, suggesting clinically significant ADHD traits. There was no
significant effect of Age or interaction between group and Age within this model, as the
trajectory in children with NF1 paralleled the trajectory of TD children over time, suggesting
similar patterns of change over time. There was no significant difference in CBCL score

160 between male and female participants.

#### 161 Autism trait development

Mean total ADOS-2 scores were higher in the NF1 group as compared to the TD group. 48% of NF1 participants at 24 months scored above threshold for autism on the ADOS-2 or BOSA-MV instruments, compared to 0% of TD children ( $X^2(1) = 15.51$ , p<0.001) (**Table 3**). More male than female participants reached instrumental threshold for autism in the NF1 group ( $X^2$ (1) = 6.24, p=0.01).

At 36 months, 31% of participants in the NF1 group scored above threshold for autism on the ADOS-2 or BOSA. This was not statistically significant ( $X^2(1) = 0.21$ , p=0.65), as 25% of TD participants also scored above threshold (although no TD participants gained an eventual research classification of autism) (**Table 3**). There were no statistically significant sex differences between the autism and non-autism participants in either the NF1 ( $X^2(1) = 2.52$ , p=0.11) or TD groups ( $X^2(1) = 1.11$ , p=0.29).

On the ADI-R at 36 months, there were significant differences, with higher mean scores on
each of the 4 subscales in NF1 compared to TD participants (p<0.001) (Figure 4 and Table</li>
3).

When combining the ADI-R and ADOS-2/BOSA at 36 months to give a research classification of autism, as detailed in the **Supplementary materials**, 14% of the NF1 cohort met criteria for autism compared to 0% of TD participants; this was also statistically not significant ( $X^2(1) =$ 2.71, p=0.10) (**Table 3**).

#### 180 DISCUSSION

To our knowledge, this is the first study to systematically investigate the developmental trajectories of cognitive and behavioural development in children with NF1 from 5 to 36 months of age using both objective and parental report measures. Our study suggests significantly lower trajectories of cognitive, motor, language and adaptive behaviour

development in the NF1 group, with an overall mean difference that strengthens overdevelopmental time and is clear by 24 months of age.

On the MSEL, lower scores are first evident at 5 months, but these differences are 187 strengthened by 24 months, and remain at 36 months. These results are consistent with a 188 previous longitudinal study which showed significantly lower cognitive function in NF1 at 21 189 months of age, which remained at the follow-up evaluation at 40 months.<sup>14</sup> It is interesting to 190 note that only subtle group differences in cognitive functioning were observed at 10 and 14 191 months. Our previous reports on the same cohort suggest differences arising in infancy in 192 early auditory habituation and visual attention. Using an auditory habituation paradigm, 193 Begum-Ali et al (2021) found developmental differences in auditory processing in infants 194 195 with NF1 at 10 and 14 months, possibly suggestive of alterations in early sensory processing and specialisation.<sup>16</sup> Such early-stage processing differences that typically present in the first 196 year of life may represent the beginning of a series of compensatory and adaptive brain 197 processes that trigger an alternative trajectory of subsequent development.<sup>25,26</sup> Further, based 198 on the results of the parent rated VABS, there may be differences in the pace of 199 developmental change in the NF1 group with periods of 'catch-up' over time. 200 Our results indicate that levels of ADHD traits are higher in the NF1 group but were in the 201 clinically significant range for only 10.5% at 36 months. Behavioural features of ADHD 202 generally tend to peak in the school-age period, which has also been noted in NF1 with rates 203 of ADHD as high as 50%.<sup>6</sup> Animal model studies suggest that dopaminergic dysfunction in 204 NF1 underlies attentional deficits.<sup>27</sup> Clinically, the ADHD symptomatology seen in NF1 is 205 very similar to idiopathic ADHD. However, in-depth analyses of neurophysiological 206 processes underlying attention difficulties in NF1 suggests differences in cognitive control 207

208 processes. Further understanding of these processes will be needed to move away from

209 generic pharmacological intervention for ADHD and develop more personalised approaches.

13

210 Of note, only 3 participants at 36 months gained a T-score >65 however all of these

211 participants also met research criteria for autism, in keeping with previous research indicating

that autism and ADHD often co-occur in NF1 children.<sup>6</sup>

We hypothesised that higher proportions of the NF1 cohort would demonstrate autism traits 213 on administered instruments at 24 and 36 months compared to TD participants. Almost half 214 of the NF1 sample met instrumental threshold for autism at 24 months on the observer rated 215 measures, but this was somewhat attenuated at 36 months (31%). When combining both the 216 parental interview (ADI-R) and the observer rated measures (ADOS-2 or BOSA-MV), 14% 217 of the NF1 sample met research classification for autism at 36 months. These results were 218 statistically non-significant (most likely due to sample size), however they are consistent with 219 220 previous studies which suggested rates of co-occurring autism in NF1 between 10-25%.<sup>7</sup> Given that the autism behavioural phenotype in NF1 is broadly similar to idiopathic autism,<sup>28</sup> 221 it will be important to identify similarities and differences in early-stage markers in the two 222

cohorts.

Consistent with a previous longitudinal study of NF1 children aged 21-40 months,<sup>13</sup> we 224 largely found no sex differences in the trajectories of cognitive, behavioural or social 225 development. These sex differences may emerge at a later timepoint, as there are significant 226 sex differences observed in cross-sectional studies in school-age children with NF1. Males 227 228 are more likely to demonstrate differences in learning and social functioning, mirroring the pattern seen in the general population.<sup>5,29</sup> Longitudinal studies of infants with high familial 229 likelihood of neurodevelopmental conditions such as autism or ADHD have found that 230 females in general perform better than males in all dimensions of cognitive functioning.<sup>30</sup> 231 Alternatively, sex differences may not have been noted in our sample due to the relatively 232 233 small sample size.

Methodological strengths of our study included tracking of a prospectively ascertained 234 sample of children with NF1. Limitations include a relatively small sample size due to 235 236 variable retention and rolling recruitment. The NF1 group was composed primarily of children with an inherited pathogenic variant, due to the early age at which assessments 237 238 began. Our TD group showed a higher than expected proportion of participants reaching 239 threshold for autism at 36 months on the ADOS-2/BOSA, however when combined with the 240 ADI-R, none of the TD group was given a research classification of autism. Due to COVID limitations we utilised the BOSA for some participants, which is administered online and 241 242 may not gather as accurate a picture of traits as ADOS-2. Finally, research thresholds using the ADI-R and ADOS/BOSA rather than gold-standard clinical best estimates were used for 243 the autism classification in the NF1 cohort. 244

#### **CONCLUSION** 245

246 Our results collectively suggest that the NF1 brain development is atypical, with early-stage sensory processing difficulties seen in infancy consolidated to behavioural phenotypic 247 differences by 24 months.<sup>15,16</sup> Clinically, this highlights that developmental monitoring and 248 249 referral for early interventions should be considered by the age of 2 in children with NF1. Intervention targeting neurocognitive modifiers such as executive attention or social 250 engagement may ameliorate the impact of genetic or environmental vulnerabilities on the 251 developing brain.<sup>29</sup> Future work should include replication of our findings in larger cohorts, 252 investigating the similarities and differences in the developmental profiles seen in NF1 to 253 other cohorts of infants at higher likelihood of common neurodevelopmental conditions such 254 as autism and ADHD. This will inform potential intervention development. 255

#### 256 Acknowledgments

257

We are extremely grateful to the families who have given their time for our research, and NF

charities particularly Nerve Tumours UK and Childhood Tumour Trust. We would like to

thank the researchers who assisted with recruitment and data collection; Kim Davies, Janice

260 Fernandes, Marian Greensmith, Natalie Vaz, Claire Bennett, Olivia Mitchell, Imogen Crook,

- 261 Amelia Pearson, Henna Ahmed and Sofia Ahmed. We are grateful to the placement students
- who assisted with data collection; Francesca Conti, Zoë Freeman and Meg Jackson.

#### 263 Members of the EDEN-STAARS team

- 264 The STAARS team includes: Mary Agyapong, Tessel Bazelmans, Leila Dafner, Mutluhan
- 265 Ersoy, Teodora Gliga, Amy Goodwin, Rianne Haartsen, Hanna Halkola, Alexandra Hendry,
- 266 Rebecca Holman, Sarah Kalwarowsky, Sarah Lloyd-Fox, Luke Mason, Nisha Narvekar, Laura
- 267 Pirazzoli and Chloë Taylor.
- 268 The EDEN team includes: Grace Vassallo, Judith Eelloo, D. Gareth Evans, Siobhan West,
- 269 Eileen Hupton, Louise Robinson, Neeta Lakhani, Brian Wilson, Deborah Osio, Charles Shaw-
- 270 Smith, Natalie Canham and Saba Sharif.

### REFERENCES

1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. (2010). Birth 271 incidence and prevalence of tumor-prone syndromes: estimates from a UK family 272 genetic register service. Am J Med Genet A.152A(2):327-332. 10.1002/ajmg.a.33139 273 Klein-Tasman BP, Janke KM, Luo W, Casnar CL, Hunter SJ, Tonsgard J, et al. 2. 274 275 (2014). Cognitive and psychosocial phenotype of young children with neurofibromatosis-1. J Int Neuropsychol Soc.20(1):88-98. 276 10.1017/S1355617713001227 277 3. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. (2021). 278 279 Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med.23(8):1506-1513. 280 281 10.1038/s41436-021-01170-5 4. Brei NG, Klein-Tasman BP, Schwarz GN, Casnar CL. (2014). Language in young 282 children with neurofibromatosis-1: relations to functional communication, attention, 283 and social functioning. Res Dev Disabil.35(10):2495-2504. 284 10.1016/j.ridd.2014.06.016 285

286	5.	Hyman SL, Shores A, North KN. (2005). The nature and frequency of cognitive
287		deficits in children with neurofibromatosis type 1. <i>Neurology</i> .65(7):1037-1044.
288		10.1212/01.wnl.0000179303.72345.ce
289	6.	Garg S, Lehtonen A, Huson SM, Emsley R, Trump D, Evans DG, et al. (2013).
290		Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from
291		a population-based study. Dev Med Child Neurol.55(2):139-145.
292		10.1111/dmcn.12043
293	7.	Chisholm AK, Anderson VA, Pride NA, Malarbi S, North KN, Payne JM. (2018).
294		Social Function and Autism Spectrum Disorder in Children and Adults with
295		Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis. Neuropsychol
296		<i>Rev</i> .28(3):317-340. 10.1007/s11065-018-9380-x
297	8.	Beaussart-Corbat ML, Barbarot S, Farges D, Martin L, Roy A. (2021). Executive
298		functions in preschool-aged children with neurofibromatosis type 1: Value for early
299		assessment. J Clin Exp Neuropsychol.43(2):163-175.
300		10.1080/13803395.2021.1893277
301	9.	Casnar CL, Klein-Tasman BP. (2017). Parent and Teacher Perspectives on Emerging
302		Executive Functioning in Preschoolers With Neurofibromatosis Type 1: Comparison
303		to Unaffected Children and Lab-Based Measures. J Pediatr Psychol.42(2):198-207.
304		10.1093/jpepsy/jsw042
305	10.	Lorenzo J, Barton B, Acosta MT, North K. (2011). Mental, motor, and language
306		development of toddlers with neurofibromatosis type 1. J Pediatr. 158(4):660-665.
307		10.1016/j.jpeds.2010.10.001
308	11.	Lorenzo J, Barton B, Arnold SS, North KN. (2013). Cognitive features that
309		distinguish preschool-age children with neurofibromatosis type 1 from their peers: a
310		matched case-control study. J Pediatr. 163(5):1479-1483 e1471.
311		10.1016/j.jpeds.2013.06.038
312	12.	Soucy EA, Gao F, Gutmann DH, Dunn CM. (2012). Developmental delays in
313		children with neurofibromatosis type 1. J Child Neurol.27(5):641-644.
314		10.1177/0883073811423974
315	13.	Garg S, Wan MW, Begum-Ali J, Kolesnik-Taylor A, Green J, Johnson MH, et al.
316		(2022). Early Developmental Trajectories in Infants With Neurofibromatosis 1. Front
317		Psychol.13:795951. 10.3389/fpsyg.2022.795951
318	14.	Lorenzo J, Barton B, Arnold SS, North KN. (2015). Developmental trajectories of
319		young children with neurofibromatosis type 1: a longitudinal study from 21 to 40
320		months of age. J Pediatr. 166(4):1006-1012 e1001. 10.1016/j.jpeds. 2014. 12.012
321	15.	Wessel LE, Gao F, Gutmann DH, Dunn CM. (2013). Longitudinal analysis of
322		developmental delays in children with neurofibromatosis type 1. J Child
323		Neurol.28(12):1689-1693. 10.1177/0883073812462885
324	16.	Begum-Ali J, Kolesnik-Taylor A, Quiroz I, Mason L, Garg S, Green J, et al. (2021).
325		Early differences in auditory processing relate to Autism Spectrum Disorder traits in
326		infants with Neurofibromatosis Type I. J Neurodev Disord.13(1):22. 10.1186/s11689-
327		021-09364-3
328	17.	Carter Leno V, Begum-Ali J, Goodwin A, Mason L, Pasco G, Pickles A, et al. (2022).
329		Infant excitation/inhibition balance interacts with executive attention to predict
330		autistic traits in childhood. Mol Autism.13(1):46. 10.1186/s13229-022-00526-1
331	18.	Mullen EM. Mullen scales of early learning (AGS ed.). Circle Pines, MN: American
332		Guidance Service Inc.; 1995.
333	19.	Sparrow SS. Vineland Adaptive Behavior Scales. In: Kreutzer JS, DeLuca J, Caplan
334		B, editors. Encyclopedia of Clinical Neuropsychology. New York, NY: Springer New
335		York; 2011. p. 2618-2621.

336 337	20.	Achenbach TMaR, L.A. <i>Manual for the ASEBA School-Age Forms and Profiles</i> . Burlington, VT: University of Vermont Research Center for Children, Youth, &
338		Families; 2001.
339	21.	Lord C, Risi S, Lambrecht L, Cook EH, Jr., Leventhal BL, DiLavore PC, et al.
340		(2000). The autism diagnostic observation schedule-generic: a standard measure of
341		social and communication deficits associated with the spectrum of autism. J Autism
342		<i>Dev Disord</i> .30(3):205-223.
343	22.	Luyster R, Gotham K, Guthrie W, Coffing M, Petrak R, Pierce K, et al. (2009). The
344		Autism Diagnostic Observation Schedule-toddler module: a new module of a
345		standardized diagnostic measure for autism spectrum disorders. J Autism Dev
346		Disord.39(9):1305-1320. 10.1007/s10803-009-0746-z
347	23.	Dow D, Holbrook A, Toolan C, McDonald N, Sterrett K, Rosen N, et al. (2022). The
348		Brief Observation of Symptoms of Autism (BOSA): Development of a New Adapted
349		Assessment Measure for Remote Telehealth Administration Through COVID-19 and
350		Beyond. J Autism Dev Disord.52(12):5383-5394. 10.1007/s10803-021-05395-w
351	24.	Lord C, Rutter M, Le Couteur A. (1994). Autism Diagnostic Interview-Revised: a
352		revised version of a diagnostic interview for caregivers of individuals with possible
353		pervasive developmental disorders. J Autism Dev Disord.24(5):659-685.
354		10.1007/BF02172145
355	25.	Johnson MH, Jones EJ, Gliga T. (2015). Brain adaptation and alternative
356		developmental trajectories. Dev Psychopathol.27(2):425-442.
357		10.1017/S0954579415000073
358	26.	Johnson MH, Charman T, Pickles A, Jones EJH. (2021). Annual Research Review:
359		Anterior Modifiers in the Emergence of Neurodevelopmental Disorders (AMEND)-a
360		systems neuroscience approach to common developmental disorders. J Child Psychol
361		Psychiatry.62(5):610-630. 10.1111/jcpp.13372
362	27.	Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Wozniak DF, Gutmann DH.
363		(2013). Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.
364		Ann Neurol.73(2):309-315. 10.1002/ana.23793
365	28.	Chisholm AK, Haebich KM, Pride NA, Walsh KS, Lami F, Ure A, et al. (2022).
366		Delineating the autistic phenotype in children with neurofibromatosis type 1. Mol
367		Autism.13(1):3. 10.1186/s13229-021-00481-3
368	29.	Garg S, Heuvelman H, Huson S, Tobin H, Green J, Northern UKNFRN. (2016). Sex
369		bias in autism spectrum disorder in neurofibromatosis type 1. J Neurodev
370		Disord.8:26. 10.1186/s11689-016-9159-4
371	30.	Messinger DS, Young GS, Webb SJ, Ozonoff S, Bryson SE, Carter A, et al. (2015).
372		Early sex differences are not autism-specific: A Baby Siblings Research Consortium
373		(BSRC) study. Mol Autism.6:32. 10.1186/s13229-015-0027-y
374	31.	Risi S, Lord C, Gotham K, Corsello C, Chrysler C, Szatmari P, et al. (2006).
375		Combining information from multiple sources in the diagnosis of autism spectrum
376		disorders. J Am Acad Child Adolesc Psychiatry.45(9):1094-1103.
377		10.1097/01.chi.0000227880.42780.0e

#### **TABLES AND FIGURES**

**Figure 1:** Estimated marginal mean scores of NF1 and TD groups on the Mullen Scale of Early Learning at 5, 10, 14, 24 and 36 months. Error bars represent 95% confidence intervals.




Figure 2: Estimated marginal mean scores of NF1 and TD groups on the Vineland Adaptive Behaviour Scale at 5, 10, 14, 24 and 36 months. Error bars represent 95% confidence intervals.




Figure 3: Estimated marginal mean scores of NF1 and TD groups on the CBCL-DSM ADHD Subscale (T scores used) at 24 and 36 months. Error bars represent 95% confidence intervals.





Figure 4: Mean values and Mann-Whitney results for subscales A-D on the Autism Diagnostic Interview-Revised (ADI-R). A – qualitative abnormalities in reciprocal social interaction, B – qualitative abnormalities in communication, C - restricted, repetitive and stereotyped patterns of behaviour and D – abnormalities of development evident at or before 36 months.

ADI-R



	Mann-Whitney scores
A:Reciprocal Social Interaction	Mean rank 14.14 vs 30.72, U=83.50, z=-4.03, p=<0.001*
B:Communication	Mean rank 14.39 vs 30.57, U=88.00, z=-3.95, p=<0.001*
C:Restrictive, Repetitive, Stereotyped Behaviour	Mean rank 16.50 vs 29.30, U=126.00, z=-3.23, p=0.001*
D:Abnormalities evident at or before 36 months	Mean rank 12.81 vs 31.52, U=59.50, z=-4.79, p=<0.001*

# Table 1: Demographic characteristics and number of participants at each Timepoint

	5 Months					10 M	onths	14 Months 24 months						36 months						
	TD group		TD group NF1 Group		TD group NF1 Group		TD group NF1 Group		TD group		N	NF1 Group		TD group		NF1 Group				
	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean
		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]
Age at time of testing in days	26	179.19 [14.05]	15	194.73 [17.85]	27	321.93 [16.70]	23	327 [17.11]	23	447.7 [18.37]	27	449.74 [23.41]	24	762.25 [36.07]	29	795.41 [90.98]	20	1135.45 [55.31]	30	1255.93 [164.87]
Sex (n) M/F	26	17/9	15	8/7	27	16/11	23	12/11	23	13/10	27	13/ 14	24	13/11	29	14/15	20	12/8	30	14/16
Maternal education (n) (Secondary/undergrad/ postgrad)	23	2/8/13	12	8/2/2	26	2/10/14	23	15/5/3	23	2/7/14	25	14/8/3	23	2/8/13	26	15/8/3	19	1/7/11	26	16/7/3

Table 2: Linear mixed modelling F statistic and p values of fixed effects for all the outcome measures. Maternal education was included in all
models as a covariate. df= degrees of freedom, F statistic, p value, *= significant results

													MSE	L Early Lea	arning	
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$			MS	SEL Fine M	otor	MSEL Receptive Language			MSEL	Expressive L	anguage	Composite			
	df	F	Р	df	F	р	df	F	р	df	F	р	df	F	р	
Intercept	1, 56	3567.94	<.001*	1,53	1786.79	<.001*	1, 53	3036.60	<.001*	1, 56	2590.40	<.001*	1, 53	4364.92	<.001*	
Group	1, 56	84.72	<.001*	1,53	64.16	<.001*	1, 53	111.37	<.001*	1, 57	36.59	<.001*	1, 53	85.30	<.001*	
Timepoint	4, 178	38.46	<.001*	4, 174	7.11	<.001*	4, 177	53.75	<.001*	4, 179	19.57	<.001*	4, 170	61.97	<.001*	
Sex	1, 54	0.18	.676	1, 51	0.17	.679	1, 50	0.38	.541	1, 54	1.33	.254	1, 51	0.20	.657	
Group x Timepoint	4, 178	30.83	<.001*	4, 174	13.65	<.001*	4, 177	23.51	<.001*	4, 179	20.03	<.001*	4,170	41.30	<.001*	

	VABS Communication			VABS Daily Living Skills			VABS Socialization			VA	BS Motor SI	cills	Composite			
	df	F	р	df	F	р	df	F	р	df	F	р	df	F	р	
Intercept	1,50	7107.57	<.001*	1, 55	8034.63	<.001*	1, 59	7396.78	<.001*	1, 54	5814.12	<.001*	1, 57	6986.46	<.001*	
Group	1, 50	14.15	<.001*	1, 55	5.60	.022*	1, 59	2.02	.160	1, 54	22.55	<.001*	1, 57	13.92	<.001*	
Timepoint	4, 148	10.97	<.001*	4, 156	9.57	<.001*	4, 150	3.72	.006*	4, 149	12.24	<.001*	4, 143	8.24	<.001*	
Sex	1,48	1.39	.245	1, 53	1.84	.180	1, 58	2.34	.132	1, 53	.52	.475	1, 56	2.29	.136	
Group x Timepoint	4, 148	6.78	<.001*	4, 156	3.95	.004*	4, 150	5.31	<.001*	4, 149	2.65	.035*	4, 143	8.22	<.001*	

	СВС	CL DSM-AI	OHD	
		Subscale		
	df	F	р	
Intercept	1,50	6252.67	<.001*	
Group	1, 50	11.21	.002*	
Timepoint	1,46	0.02	.885	
Sex	1, 50	1.97	.167	
Group x Timepoint	1,46	0.85	.361	
Group x runepoint	1,40	0.05	.501	

24

Vineland Adaptive Behaviour

Table 3: Descriptive statistics including means and SDs for the NF1 and TD group at 24 and 36 month time points for ADI-R, ADOS, BOSA and CBCL

		24 m	onths		36 months					
	]	ГD group	N	NF1 Group		ГD group	N	F1 Group		
	n	Mean	n	Mean	n	Mean	n	Mean		
		[SD]		[SD]		[SD]		[SD]		
Autism Diagnostic Interview - Revised (ADI-R) Diagnostic Algorithm										
Qualitative Abnormalities in Reciprocal Social Interaction (A)					18	0.94(1.00)	30	5.23(4.79)		
Qualitative Abnormalities in Communication (B)					18	0.67 (0.97)	30	5.03(4.42)		
Restricted, Repetitive and Stereotyped Patterns of Behaviour (C)		N/A		N/A	18	0.39 (0.61)	30	2.13(2.60)		
Abnormality of Development Evident at or Before 36 Months (D)					18	0.06 (0.24)	30	1.83(1.34)		
Meeting threshold for autism on ADI-R					18	0 (0%)	30	5 (17%)		
Not meeting threshold for autism on ADI-R					18	18 (100%)	30	25 (83%)		
Autism Diagnostic Observation Schedule-2 (ADOS-2)										
Module (n) (Toddler/Module 1/Module 2)	24	24,0,0	24	21,3,0	20	0,0,20	17	0,16,1		
Total scores	24	3.67(1.95)	24	8.08(6.64)	20	4.35(3.42)	17	4.47(3.86)		
Social Affect scores	24	3.13(1.80)	24	6.83(5.75)	20	3.60(2.84)	17	3.65(3.02)		

Restrictive and Repetitive Behaviour scores	24	0.54(0.72)	24	1.25(1.29)	20	0.80(0.95)	17	0.82(1.24)
Number reaching threshold for Autism Spectrum Disorder or Autism on ADOS-2	24	0 (0%)	24	11 (46%)	20	5 (25%)	17	4 (24%)
Brief Observation of Symptoms of Autism (BOSA-MV)								
Module (n) (Toddler/Module 1)			3	2,1			12	0,12
Total scores	0	0,0	3	12.33(4.93)	0	0,0	12	8.17(2.66)
Algorithm scores			3	6.00(2.00)			12	4.42(1.44)
Number reaching threshold for Autism Spectrum Disorder on the BOSA			3	2 (67%)			12	5 (42%)
ADOS/BOSA combined								
Number of participants reaching threshold for Autism	24	0 (0%)	27	13 (48%)	20	5 (25%)	29	9 (31%)
Number of participants not reaching threshold for Autism	24	24 (100%)	27	14 (52%)	20	15 (75%)	29	20 (69%)
Number of participants reaching threshold for Autism on both								
ADI-R and ADOS/BOSA		N/A		N/A	18	0 (0%)	29	4 (14%)
Child Behaviour Checklist ADHD subscale								
T score	22	51.86(2.49)	27	55.56(7.84)	21	51.10(1.45)	28	57.14(6.88)

#### **Supplementary materials**

#### Procedure

The study assessments took place at the Division of Psychology and Mental Health, University of Manchester, and the Centre for Brain and Cognitive Development, Birkbeck, University of London. Prior written informed consent was obtained from the parent. Testing took place if the child was physically well and content. Participant families were provided with reimbursement for expenses. The behavioural measures described below were part of a more comprehensive experimental protocol.

#### Measures

*ADOS-2*: Based on the expressive language ability of the participants, either the Toddler module, Module 1 or Module 2 of the ADOS-2 were used at 24 and 36 months (**Table 2**). Coding was carried out from videos, with an inter-rater reliability of 79.1% for the NF1 cohort.

*BOSA-MV*: Based on the expressive language ability of the participants, either the Toddler module or Module 1 of the BOSA-MV were used at 24 and 36 months (**Table 2**).

ADI-R: Four subscales are produced: A – qualitative abnormalities in reciprocal social interaction, B – qualitative abnormalities in communication, C – restricted, repetitive and stereotyped patterns of behaviour and D – abnormalities of development evident at or before 36 months. Each subscale has an algorithm score cut-off for Autism.

#### **Classification of autism**

In our paper, the following thresholds are used on the ADOS-2 and BOSA-MV to indicate autism traits at 24 months:

- 'mild-to-moderate' or 'moderate-to-severe' concern on the ADOS-2 Toddler module

- 'autism-spectrum' or 'autism' on ADOS-2 Module 1

- a score of 6 on the BOSA-MV toddler module or a score of 5 on the BOSA-MV Module 1.

Luyster et al (2009) state that at least 95% of children with Autism Spectrum Disorder and no more than 10% of typically developing children would fall into the two groups suggesting clinical concern on the ADOS Toddler module (mild-to-moderate and moderate-to-severe).<sup>22</sup> Dow et al (2022) recommend a cut-off of 6 for Autism Spectrum Disorder for the BOSA-MV toddler module and a score of 5 as a cut-off for the BOSA-MV Module 1.<sup>23</sup>

#### Participants were assigned a research instrumental classification of autism at 36 months if they scored either:

- 'autism-spectrum' or 'autism' on ADOS-2 Module 1 or 2

- a cut off of 5 on the BOSA-MV Module 1

### AND

- Met threshold for subscale A and came within one point of B, or met B and came within one point of A on the ADI-R, as suggested by Risi et al (2006).<sup>31</sup>

#### **Study numbers**

Flowchart showing the number of NF1 and TD participants at each time point in the study. Flexible recruitment and variable retention across visits meant that the sample size varied between time points.



5 visi	its NF1=8, TD=15
4 visi	its NF1=12, TD=9
3 visi	its NF1=9, TD=2
2 visi	its NF1=3, TD=0
1 visi	it NF1=3, TD=3
Total	l number of NF1 participants = 35
Total	l number of TD participants = 29

Descriptive statistics including means and SDs for the NF1 and TD group at the five assessment time points for Mullen Scales of Early Learning and Vineland Adaptive Behaviour Scale

	5 Months					10 Months				14 Months				24 months				36 months			
	TD group		NF1 Group		TD group		NF1 Group		TD group		NF1 Group		TD group		NF1 Group		TD group		N	F1 Group	
	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	n	Mean	
		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]		[SD]	
Mullen Scale of Early Learning T scores																					
Gross Motor	26	43.69 [9.41]	15	37.40 [9.72]	27	34.89 [11.78]	23	30.00 [10.25]	23	36.74 [13.38]	27	31.96 [12.75]	-	-	26	35.04 [8.45]	-	-	-	-	
Visual reception	26	47.27 [6.33]	15	37.47 [11.53]	27	48.85 [7.99]	23	43.96 [8.08]	23	35.09 [8.88]	27	33.67 [5.17]	24	59.63 [10.66]	27	33.11 [9.83]	19	67.58 [9.34]	27	40.63 [8.65]	
Fine motor Receptive language	26	42.92 [10.46]	15	32.8 [6.99]	27	51.63 [12.88]	23	42.13 [11.29]	23	49.65 [12.18]	27	43.85 [11.07]	24	56.00 [12.98]	27	33.89 [10.49]	19	64.68 [11.32]	27	31.22 [9.67]	
Expressive language	26	36.88 [11.28]	14	25.71 [9.31]	27	39.26 [8.96]	23	34.87 [7.73]	23	32.87 [6.50]	27	28.33 [6.01]	24	57.67 [8.73]	27	33.85 [10.65]	19	65.84 [6.30]	27	35.89 [9.70]	
Early Learning Composite Scores	26 26	41.85 [7.45] 85.00[9.32]	15 14	35.13 [6.35] 67.86 [9.46]	27 27	36.85 [9.89] 88.89 [12.19]	23 23	39.35 [12.56] 81.13 [10.70]	23 23	37.09 [8.81] 78.78 [11.99]	27 27	38.19 [10.18] 73.67 [7.30]	24 24	55.42 [12.30] 114.25[17.91]	27 27	34.52 [8.70] 81.48[17.91]	19 19	60.84 [8.51] 129.05[11.75]	26 26	39.50 [10.57] 75.88[13.45]	
												[]									

Vineland Adaptive Behaviour Scale Standard Scores																				
Communication																				
Daily living skills	22	94.95 [10.91]	14	95.71 [14.04]	21	92.86 [12.76]	23	86.13 [14.91]	19	96.11 [10.49]	24	91.04 [10.08]	22	112.14 [8.82]	22	93.41 [7.5]	12	105.08 [8.58]	30	90.73 [14.23]
Socialisation	22	86.32 [19.86]	14	92.71 [18.26]	22	102.45 [10.76]	23	93.74 [9.14]	18	93.44 [8.39]	23	95.52 [10.85]	22	108.36 [7.36]	22	96.14 [9.25]	12	104 [10.06]	30	97.9 [14.67]
Motor	23	98.70 [12.26]	14	101.36 [14.21]	22	98.77 [10.04]	21	92.76 [14.59]	18	94.22 [9.79]	23	97.96 [9.43]	22	104.64 [7.86]	22	94.55 [7.71]	12	103.25 [6.05]	30	98.47 [15.78]
Adaptive behaviour	21	88.67 [12.99]	14	85.07 [13.37]	21	95.76 [16.86]	23	79.91 [14.86]	18	101.67 [9.49]	24	93.42 [11.14]	22	102.41 [7.93]	22	93.05 [8.67]	12	92 [8.52]	30	83.77 [13.13]
composite	19	90.63 [11.93]	14	92.29 [11.13]	20	96.80 [10.44]	21	85.86 [12.85]	17	95.29 [9.73]	23	93.17 [9.36]	22	108.05 [8.16]	22	92.73 [5.78]	12	100.92 [8.58]	30	91.4 [14.62]

\*Missing data not included in n, mean or SD but kept in model for imputation

Post-hoc T-test analysis for the NF1 and TD group means at the five assessment time points for Mullen Scales of Early Learning and Vineland Adaptive Behaviour Scale. Bonferroni corrected alpha value =<0.01

	5 Months T-test	10 Months T-test	14 Months T-test	24 Months T-test	36 Months T-test
	(NF1 group – TD group)	(NF1 group – TD group)	(NF1 group – TD group)	(NF1 group – TD group)	(NF1 group – TD group)
Mullen Scale of Early Learning T Scores					
Visual Reception Fine Motor Receptive Language Expressive Language Early Learning Composite Scores	t(39)=-3.53, p<0.001* t(39)=-3.34, p=0.002* t(38)=-3.17, p=0.003* t(39)=-2.93, p=0.006* t(38)=-5.52, p<0.001*	t(48)=-2.15, p=0.037 t(48)=-2.75, p=0.008* t(48)=-1.84, p=0.072 t(48)= 0.79, p=0.436 t(48)=-2.37, p=0.022	t(48)=-0.70, p=0.485 t(48)=-1.76, p=0.084 t(48)=-2.56, p=0.014 t(48)=-0.40, p=0.688 t(48)=-1.85, p=0.07	t (49)=-9.24, p<0.001* t(49)=-6.72, p<0.001* t(49)=-8.67, p<0.001* t(49)=-7.06, p<0.001* t(49)=-6.41, p<0.001*	$\begin{array}{l} t(44) =& -10.07, \ p < 0.001 * \\ t(44) =& -10.77, \ p < 0.001 * \\ t(44) =& -11.80, \ p < 0.001 * \\ t(44) =& -7.24, \ p < 0.001 * \\ t(44) =& -13.80, \ p < 0.001 * \end{array}$
Vineland Adaptive Behaviour Scale Standard Scores Communication Daily Living Skills Socialization Motor Skills Adaptive Behaviour Composite	$\begin{array}{c} t(34)=0.182, \ p=0.857\\ t(34)=0.971, \ p=0.338\\ t(35)=0.603, \ p=0.550\\ t(33)=-0.793, \ p=0.433\\ t(31)=0.405, \ p=0.688 \end{array}$	t(42)=-1.601, p=0.117 t(43)=-2.933, p=0.005* t(41)=-1.580, p=0.122 t(42)=0.585, p<0.001* t(39)=-2.983, p<0.005*	t(41)=0.79, p=0.116 t(39)=0.67, p=0.507 t(39)=1.237, p=0.223 t(40)=-2.527, p=0.16 t(38)=-0.696, p=0.490	t(42)=-7.59, p <0.001* t(42)=-4.85, p <0.001* t(42)=-4.30, p <0.001* t(42)=-3.74, p <0.001* t(42)=-7.19, p <0.001*	t(40)=-3.25, p <0.001* t(40)=-1.32, p 0.195 t(40)=-1.02, p 0.316 t(40)=-2.00, p 0.052 t(40)=-2.11, p 0.042

**NF1 vs TD at 5 months:** Visual Reception [t(39)=-3.53, p<0.001, CI (-15.42 to -4.18)],Fine Motor [t(39)=-3.34, p=0.002, CI (-16.26 to -3.98)], Receptive Language [t(38)=-3.17, p=0.003, CI (-18.31 to -4.03)], Expressive Language [t(39)=-2.93, p=0.006, CI (-11.35 to -2.07)], Early Learning Composite [t(38)=-5.52, p<0.001, CI (-23.43 to -10.86)]. NF1 vs **TD at 10 months:** Visual Reception [t(48)=-2.15, p=0.037, CI (-9.48 to -0.31)], Fine Motor [t(48)=-2.75, p=0.008, CI (-16.45 to -2.55)], Receptive Language [t(48)=-1.84, r)p=0.072, CI (-9.19 to 0.41)], Expressive Language [t(48)= 0.79, p=0.436, CI (-3.89 to 8.88)], Early Learning Composite [t(48)=-2.37, p=0.022, CI (-14.34 to -1.18)]). NF1 vs TD at 14 months: Visual Reception [t(48)=-0.70, p=0.485, CI (-5.48 to 2.64)], Fine Motor [t(48)=-1.76, p=0.084, CI (-12.41 to 0.81)], (Receptive Language [t(48)=-2.56, p=0.014, CI (-8.09 to -0.98)], Expressive Language [t(48)=0.40, p=0.688, CI (-4.36 to 6.56)], Early Learning Composite [t(48)=-1.85, p=0.07, CI (-10.67 to 0.44)]. NF1 vs TD at 24 months: Visual Reception [t (49)=-9.24, p<0.001, CI (-32.28 to -20.75)], Fine Motor [t(49)=-6.72, p <0.001, CI (-28.72 to -15.50)], Receptive Language [t(49)=-8.67, p <0.001, CI (-29.34 to -18.29], Expressive Language [t(49)=-7.06, p <0.001, CI (-26.84 to -14.95)], Early Learning Composite [t(49)=-6.41, p <0.001, CI (-43.04 to -22.50)]. NF1 vs TD at 36 months: Visual Reception [t(44) =-10.07, p <0.001, CI (-32.35 to -21.55)], Fine Motor [t(44)=-10.77, p < 0.001, CI (-39.73 to -27.20)], Receptive Language [t(44)=-11.80, p]<0.001, CI (-35.07 to -24.84)], Expressive Language [t(44)=-7.24, p <0.001, CI (-27.29 to -15.40], Early Learning Composite [t(44)=-13.80, p < 0.001, CI (-60.94 to -45.40)].

#### VABS post hoc tests

NF1 vs TD at 5 months: Communication [t(34)=0.182, p=0.857, CI (-7.72 to 9.24)], Daily 33

living skills [t(34)=0.971, p=0.338, CI (-6.99 to 19.78)], Socialization [t(35)=0.603, p=0.550, CI (-6.30 to 11.62)], Motor Skills [t(33)=-0.793, p=0.433, CI (-12.82 to 5.63)] and Adaptive behaviour Composite [t(31)=0.405, p=0.688, CI (-6.68 to 9.99)]. NF1 vs TD at 10 months: Communication [t(34)=0.182, p=0.857, CI (-15.2 to 1.80)], Daily living skills [t(43)=-2.933, p=0.005, CI (-14.7 to -2.72)], Socialization [t(35)=0.603, p=0.550, CI (-13.69 to 1.67)], Motor Skills [t(42)=0.585, p<0.001, CI (-28.5 to -9.2)] and Adaptive behaviour Composite [t(39)=-2.983, p<0.005, CI (-18.36 to -3.52)]. NF1 vs TD at 14 months: Communication [t(41)=0.79, p=0.116, CI (-11.43 to 1.3)], Daily living skills [t(39)=0.67, p=0.507, CI (-4.20 to 8.35)], Socialization [t(39)=1.237, p=0.223, CI (-2.37 to 9.84)], Motor Skills [t(40)=-2.527, p=0.16, CI (-14.85 to -1.65)] and Adaptive behaviour Composite [t(38)=-0.696, p=0.490, CI (-8.28 to 4.04)]. NF1 vs TD at 24 months: Communication [t(42)=-7.59, p <0.001, CI (-23.71 to -13.75)], Daily living skills [t(42)=-4.85, p <0.001, CI (-17.31 to -7.14)], Socialization [t(42)=-4.30, p <0.001 CI (-14.83 to -5.36)], Motor Skills [t(42)=-3.74, p < 0.001, CI (-14.42 to -4.31)] and Adaptive behaviour Composite [t(42)=-7.19, p <0.001, CI (-19.62 to -11.02)]. NF1 vs TD at 36 months: Communication [t(40)=-3.25, p <0.001, CI (-23.27 to -5.43)], Daily living skills [t(40)=-1.32, p 0.195, CI (-15.46 to 3.26)], Socialization [t(40)=-1.02, p 0.316, CI (-14.31 to 4.75)], Motor Skills [t(40)=-2.00, p 0.052, CI (-16.54 to 0.08)] and Adaptive behaviour Composite [t(40)=-2.11, p 0.042, CI (-18.65 to -0.38)].